EIKO LIFESCIENCES LIMITED

F E E L   T H E   C H E M I S T R Y

Date: 12th August, 2026

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Wednesday, 12th August, 2026, which commenced at 1:00 PM, and concluded at 01:40 PM, Board, inter-alia, approved and taken on record the following:

1. Approved Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 along with Limited Review Report issued by the Statutory Auditors of the Company. A Copy of the same is enclosed herewith as **Annexure - I**

Thanking you,

For Eiko Lifesciences Limited

CHINTAN BHARATBHAI DOSHI
Digitally signed by CHINTAN BHARATBHAI DOSHI
Date: 2026.08.12 13:41:05 +05'30'

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: A 36190

Annexure - I

P S V Jain & Associates

Chartered Accountants

Yashwant Shopping Centre, 126, Carter Rd No. 7,
Chinchpada, Borivali East, Mumbai, Maharashtra 400066

CA INDIA

Independent Auditor's Review Report on Standalone Unaudited Financial Results Quarter ended 30th June 2026 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors
Eiko Lifesciences Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Eiko Lifesciences Limited** (The Company') for the Quarter ended 30th June 2026 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PSV JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No.: 131505W

PSV Jain & Associates FRN. 131505W Mumbai Chartered Accountants

CA Dularesh Kumar Jain
Partner
Membership No.: 137264

Place: Thane
Date: 12th August 2026

UDIN: 26137264HYHEBL8488

EIKO LIFESCIENCES LIMITED

(CIN: L65993MH1977PLC258134)

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(INR in lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
1	Revenue from operations	1,417.81	1,590.35	745.23	4,212.68
	Other income	68.34	45.44	55.37	212.93
	Total revenue	**1,486.15**	**1,635.79**	**800.60**	**4,425.61**
2	**Expenses**				
	Cost of Material consumed	1,324.50	1,587.27	460.05	3,728.41
	Changes in inventories of finished stock and work-in-progress	(40.96)	(159.35)	196.38	1.31
	Employee benefits expense	7.16	7.17	5.85	29.01
	Depreciation and amortization expense	14.74	14.74	14.75	59.02
	Finance Cost	4.06	3.82	1.82	16.29
	Other expenses	36.21	32.81	30.97	120.28
	Total expenses	**1,345.71**	**1,486.46**	**709.82**	**3,954.31**
3	**Profit/(Loss) from ordinary activities before Exceptional Items and Tax**	**140.45**	**149.33**	**90.77**	**471.30**
	Exceptional Items	-	-	-	-
4	**Profit/(Loss) from ordinary activities before Tax**	**140.45**	**149.33**	**90.77**	**471.30**
5	**Tax expense:**				
	(1) Current tax	32.65	34.72	19.93	104.93
	(2) Deferred tax	1.36	2.21	1.62	8.25
6	**Profit/(Loss) from ordinary activities after tax**	**106.44**	**112.39**	**69.22**	**358.11**
7	Other Comprehensive Income (OCI) (net of taxes)			-	
8	**Total Comprehensive Income**	**106.44**	**112.39**	**69.22**	**358.11**
9	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,434.59	1,434.59	1,376.27	1,434.59
10	Other Equity				4,909.65
11	**Earnings Per Share (EPS) (Not annualised)**				
	(1) Basic	0.74	0.80	0.50	2.60
	(2) Diluted	0.62	0.74	0.50	2.54

NOTES

1. The Standalone Financial Results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and recommended to the Board, which was thereafter approved by the Board of Directors of the Company at its meeting held on 12th August 2026.
2. The company has a single business segment, namely "Speciality & Fine Chemicals", therefore in the context of Ind AS 108, disclosure of segment information is not applicable.
3. The figures for the Quarter ended 31st March 2026 are the balancing figures between audited figures in respect of the full financial year 2025-26 and the published year to date figures upto the third quarter of the financial year 2025-26.
4. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification.

For Eiko LifeSciences Limited

L.K.Sabnis

EIKO LIFESCIENCES LIMITED Thane (W) 400604

Laxmikant Kabra
Chairman
DIN: 00061346

Date: 12th August 2026
Place: Thane

P S V Jain & Associates
Chartered Accountants
Yashwant Shopping Centre, 126, Carter Rd No. 7,
Chinchpada, Borivali East, Mumbai, Maharashtra 400066

Independent Auditor's Review Report on Consolidated Unaudited Financial Results for Quarter ended 30th June 2026 of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To the Board of Directors
Eiko LifeSciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results (the Statement') of Eiko LifeSciences Limited (the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group') and its associate for the quarter ended 30th June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. The statement includes the results of following entity:

	Parent
1	Eiko LifeSciences Limited
	Subsidiary
2	Eiko Scientific Solutions LLP
3	Eikovivify Logistics Private Limited
	Associate
4	Reflux Pharmaceuticals Private Limited
5	SSM Formulations Private Limited

4. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable Principles laid down in Indian Accounting

Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

6. We did not review the interim financial results of 2 associates included in the Statement whose interim financial information reflects total revenues of INR 607.10 lakhs and net profit after tax of INR 12.64 lakhs for the quarter ended 30th June 2026 as considered in the Statement. These interim financial results have been reviewed by other auditors and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of associate is based solely on the reports of the other auditors and the procedures performed by us as stated above

Our conclusion on the Statement is not modified in respect of the above matter.

For PSV JAIN & ASSOCIATES
Chartered Accountants
Firm Registration No.: 131505W

PSV Jain & Associates
FRN. 131505W
Mumbai
Chartered Accountants

CA Dularesh Kumar Jain
Partner
Membership No.: 137264

Place: Thane
Date: 12th August 2026

UDIN: 26137264QYRUBC9450

EIKO LIFESCIENCES LIMITED

(CIN: L65993MH1977PLC258134)

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

(INR in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	1,674.88	1,833.98	1,071.15	5,270.66
	Other income	41.08	12.95	26.52	97.28
	Total revenue	**1,715.96**	**1,846.93**	**1,097.66**	**5,367.94**
2	**Expenses**				
	Cost of Material consumed	1,393.79	1,665.60	545.83	4,128.22
	Changes in inventories of finished stock and WIP	(40.96)	(159.35)	284.31	1.31
	Employee benefits expense	19.91	20.77	12.56	66.63
	Depreciation and amortization expense	25.36	25.24	25.37	101.60
	Finance Cost	13.01	11.51	4.82	32.97
	Other expenses	108.40	78.40	77.34	330.74
	Total expenses	**1,519.52**	**1,642.17**	**950.22**	**4,661.47**
3	**Profit before Exceptional Items, Share of Profit in Equity Accounted Investee and Tax**	**196.44**	**204.76**	**147.44**	**706.47**
	Exceptional Items	-	-	-	-
4	**Profit before Share of Profit in Equity Accounted Investee and Tax**	**196.44**	**204.76**	**147.44**	**706.47**
	Share of profit/(loss) in equity accounted investees (net)	3.49	(2.89)	1.06	5.30
5	**Profit before tax**	**199.93**	**201.87**	**148.50**	**711.77**
6	**Tax expense:**				
	(1) Current tax	43.75	44.76	29.99	150.46
	(2) Deferred tax	5.34	7.40	6.78	28.84
7	**Profit for the period**	**150.83**	**149.72**	**111.74**	**532.47**
8	Other Comprehensive Income (OCI) (net of taxes)	-	-	-	-
9	**Total Comprehensive Income**	**150.83**	**149.72**	**111.74**	**532.47**
	Total Comprehensive Income/ (Loss) for the period attributable to:				-
	(a) Shareholders of the company	130.79	130.01	91.42	449.63
	(b) Non- controlling interests	20.04	19.70	20.31	82.84
10	**Paid up Equity Share Capital (Face Value of INR 10 each)**	**1,434.59**	**1,434.59**	**1,376.27**	**1,434.59**
11	Other Equity				5,037.66
12	**Earnings Per Share (EPS) (Not annualised)**				
	(1) Basic	0.91	0.93	0.66	3.26
	(2) Diluted	0.76	0.86	0.66	3.19

NOTES

1. The Consolidated Financial Results for the quarter ended 30th June 2026 were reviewed by the Audit Committee and recommended to the Board, which was thereafter approved by the Board of Directors of the Company at its meeting held on 12th August 2026.

2. The results of the quarter ended 31st March 2026 are balancing figures between audited results in respect of full financial year and published year to date results up to third quarter of relevant financial year and have been subjected to limited review by auditors.

3. Consolidated Financial Results include financial results of

Eiko Scientific Solutions LLP	Wholly Owned LLP
Eikovivify Logistics Private Limited	Subsidiary
Reflux Pharmaceuticals Private Limited	Associate Company
SSM Formulations Private Limited	Associate Company

4. As per Ind AS 108 "Operating Segment" the Group has reported segment information mainly under two segments:
   A. Speciality and Fine Chemicals
   B. Logistics Services

5. Figures for the previous period have been regrouped/ reclassified wherever necessary to conform to current period's classification.

For Eiko LifeSciences Limited

L.K. Sabna

EIKO LIFESCIENCES LIMITED Thane (W) 400604

Laxmikant Kabra
Chairman
DIN: 00061346

Date: 12th August 2026
Place: Thane

SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

The Group has identified two reportable business segments:

1. Speciality Chemicals & Pharma Intermediates
2. Logistics Services

The Logistics Services segment represents the core business of the Company's subsidiary, Eikovivify Logistics Private Limited, which commenced operations during the current financial year. Accordingly, segment-wise reporting has been provided for the quarter ended 30th June 2026.

(INR in Lakhs)

Sr. No.	Particulars	Quarter ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Segment Revenue**				
	a) Specialty & Fine Chemicals	1,525.32	1,688.37	840.22	4,602.75
	b) Logistics Business	149.56	145.61	230.93	667.90
	Total segment revenue	**1,674.88**	**1,833.98**	**1,071.15**	**5,270.66**
2	**Segment Results**				
	a) Specialty & Fine Chemicals	98.86	125.34	44.42	323.40
	b) Logistics Business	28.67	28.93	29.73	121.25
	Total	**127.52**	154.27	**74.15**	**444.65**
	Less: Finance Costs	-13.01	-11.51	-4.82	-32.97
	Add: Other Income	57.88	31.33	50.62	183.59
	Add: Share of Non-Controlling Interest	27.54	27.79	28.56	116.50
	Add: Exceptional Items	-	-	-	-
	Profit before tax	**199.93**	**201.87**	**148.50**	**711.77**
3	**Segment Assets**				
	a) Specialty & Fine Chemicals	4,056.11	4,337.36	3,781.52	4,337.36
	b) Logistics Business	1,594.98	1,716.31	1,073.79	1,716.31
	Total Segment Assets	**5,651.09**	**6,053.68**	4,855.31	**6,053.68**
	Investments in equity accounted investees	1,532.58	1,529.09	716.19	1,529.09
	Unallocated Assets	1,212.08	1,354.20	851.00	1,354.20
	Total Assets	**8,395.75**	**8,936.97**	**6,422.50**	**8,936.97**
4	**Segment Liabilities**				
	a) Specialty & Fine Chemicals	1,079.60	1,546.42	435.79	1,546.42
	b) Logistics Business	182.83	408.06	154.64	408.06
	Total Segment Liabilities	**1,262.43**	**1,954.49**	**590.43**	**1,954.49**
	Total Liabilities	**1,262.43**	**1,954.49**	**590.43**	**1,954.49**

EIKO LIFESCIENCES LIMITED
Thane (W)
400604